secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001178913-26-002455
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio Q1 net loss $3.5M; cash $20.4M; EB613 Phase 3 protocol submitted to FDA
--------------------------------------------------------------------------------

- Net loss of $3.5M ($0.07/share) vs $2.6M in Q1 2025; R&D expenses rose to $2.3M from $1.1M.
- Cash $20.4M as of May 8, 2026, including BVF private placement proceeds; runway into Q1 2027.
- EB613 Phase 3 protocol submitted to FDA; bridging study completed for single-tablet formulation.
- EB612 hypoparathyroidism program prioritized with OPKO; IND expected late 2026.
- Geno Germano appointed Chairman in February; Steve Rubin joined Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/0001178913-26-002455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/zk2635218.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer